Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 24.53 percent. This is a 20 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $1.999 million which missed the analyst consensus estimate of $6.473 million by 69.12 percent. This is a 77.83 percent decrease over sales of $9.018 million the same period last year.